Company / Cost of Revenue
BioRestorative Therapies, Inc. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$23.8K
FY2025
5-year range
$23.8K / $28.1K
FY2021-FY2025
Trend
-15.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $102 to $23,844 over the past 8 years.
Based on SEC 10-K filings.
$23,844 in FY2025.
Increased from $102 to $23,844 over the past 8 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, cost of revenue decreased 15.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -47.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $23.8K | -15.1% |
| FY2024 | $28.1K | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $102 | -100.0% |
| FY2016 | $261.5K | +22.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026